Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipid Therapeutics GmbH

www.lipid-therapeutics.com

Latest From Lipid Therapeutics GmbH

Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies

With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.

Commercial Deals

Nestlé Gets Serious With Seres Deal

The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, October 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.

BioPharmaceutical Medical Device

Lipid Therapeutics Plans U.S. Ulcerative Colitis Trials With Lipid Therapy

U.S. Phase III studies could start in the next 12 months with Lipid Therapeutics’ purified formulation of phosphatidylcholine to reverse deficiencies in the gastrointestinal mucosal barrier in patients with ulcerative colitis.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Lipid Therapeutics GmbH
  • Senior Management
  • Gerhard Keilhauer, PhD, CEO
  • Contact Info
  • Lipid Therapeutics GmbH
    Phone: (49) 6221 33 50 580
    P.O. Box 107 Heidelberg, 69126
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register